Regulation of γ-secretase activity in Alzheimer's disease

被引:48
|
作者
Zhou, Shuxia [1 ]
Zhou, Hua [1 ]
Walian, Peter J. [1 ]
Jap, Bing K. [1 ]
机构
[1] Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA
关键词
AMYLOID PRECURSOR PROTEIN; GLYCOGEN-SYNTHASE KINASE-3-BETA; NECROSIS-FACTOR-ALPHA; TRANSGENIC MOUSE MODEL; C-TERMINAL FRAGMENT; E EPSILON-4 ALLELE; LIPID RAFTS; APOLIPOPROTEIN-E; BETA-PROTEIN; INTRACELLULAR DOMAIN;
D O I
10.1021/bi602509c
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The gamma-secretase complex is an intramembrane aspartyl protease that cleaves its substrates along their transmembrane regions. Sequential proteolytic processing of amyloid precursor protein by beta- and gamma-secretase produces amyloid beta-peptides, which are the major components of amyloid plaques in the brains of Alzheimer's disease patients. The gamma-secretase complex is therefore believed to be critical in the pathogenesis of Alzheimer's disease. Here we review the range of factors found to affect the nature and degree of gamma-secretase complex activity; these include gamma-secretase complex assembly and activation, the integral regulatory subunit CD147, transient or weak binding partners, the levels of cholesterol and sphingolipids in cell membranes, and inflammatory cytokines. Integrated knowledge of the molecular mechanisms supporting the actions of these factors is expected to lead to a comprehensive understanding of the functional regulation of the gamma-secretase complex, and this, in turn, should facilitate the development of novel therapeutic strategies for the treatment of Alzheimer's disease.
引用
收藏
页码:2553 / 2563
页数:11
相关论文
共 50 条
  • [21] γ-Secretase as a Therapeutic Target in Alzheimer's Disease
    Guardia-Laguarta, C.
    Pera, M.
    Lleo, A.
    CURRENT DRUG TARGETS, 2010, 11 (04) : 506 - 517
  • [22] gamma-Secretase in Alzheimer's disease
    Hur, Ji-Yeun
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2022, 54 (04) : 433 - 446
  • [23] Inhibition and modulation of γ-secretase for Alzheimer's disease
    Wolfe, Michael S.
    NEUROTHERAPEUTICS, 2008, 5 (03) : 391 - 398
  • [24] Modulators of γ-Secretase Activity Can Facilitate the Toxic Side-Effects and Pathogenesis of Alzheimer's Disease
    Svedruzic, Zeljko M.
    Popovic, Katarina
    Sendula-Jengic, Vesna
    PLOS ONE, 2013, 8 (01):
  • [25] Obesity and sex interact in the regulation of Alzheimer's disease
    Moser, V. Alexandra
    Pike, Christian J.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2016, 67 : 102 - 118
  • [26] Interacting with γ-Secretase for Treating Alzheimer's Disease: From Inhibition to Modulation
    Panza, F.
    Frisardi, V.
    Solfrizzi, V.
    Imbimbo, B. P.
    Logroscino, G.
    Santamato, A.
    Greco, A.
    Seripa, D.
    Pilotto, A.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (35) : 5430 - 5447
  • [27] Decreasing the expression of PICALM reduces endocytosis and the activity of β-secretase: implications for Alzheimer's disease
    Thomas, Rhian S.
    Henson, Alex
    Gerrish, Amy
    Jones, Lesley
    Williams, Julie
    Kidd, Emma J.
    BMC NEUROSCIENCE, 2016, 17
  • [28] Plasmalogens Inhibit APP Processing by Directly Affecting γ-Secretase Activity in Alzheimer's Disease
    Rothhaar, Tatjana L.
    Groesgen, Sven
    Haupenthal, Viola J.
    Burg, Verena K.
    Hundsdoerfer, Benjamin
    Mett, Janine
    Riemenschneider, Matthias
    Grimm, Heike S.
    Hartmann, Tobias
    Grimm, Marcus O. W.
    SCIENTIFIC WORLD JOURNAL, 2012,
  • [29] γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
    Imbimbo, Bruno P.
    Giardina, Giuseppe A. M.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (12) : 1555 - 1570
  • [30] Decreasing the expression of PICALM reduces endocytosis and the activity of β-secretase: implications for Alzheimer’s disease
    Rhian S. Thomas
    Alex Henson
    Amy Gerrish
    Lesley Jones
    Julie Williams
    Emma J. Kidd
    BMC Neuroscience, 17